ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes

• Published in: The New England journal of medicine Vol. 377; no. 18; pp. 1733 - 1745
• Main Authors: Marcovecchio, M. Loredana, Chiesa, Scott T, Bond, Simon, Daneman, Denis, Dawson, Sarah, Donaghue, Kim C, Jones, Timothy W, Mahmud, Farid H, Marshall, Sally M, Neil, H. Andrew W, Dalton, R. Neil, Deanfield, John, Dunger, David B
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 02.11.2017
• Subjects: ACE inhibitors; Adolescent; Adolescents; Age; Albumin; Albuminuria - etiology; Albuminuria - prevention & control; Angiotensin-converting enzyme inhibitors; Angiotensin-Converting Enzyme Inhibitors - adverse effects; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Apolipoprotein B; Apolipoproteins; Area Under Curve; C-reactive protein; Cardiovascular diseases; Child; Cholesterol; Creatinine; Creatinine - urine; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - complications; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 1 - urine; Double-Blind Method; Drug dosages; Drug Therapy, Combination; Endocrinology; Enzymes; Female; Glomerular filtration rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Lipids - blood; Male; Medication Adherence; Peptidyl-dipeptidase A; Puberty; Risk factors; Statins; Teenagers; Triglycerides
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa1703518

Adolescents with type 1 diabetes received one of four regimens: angiotensin-converting–enzyme (ACE) inhibitor–placebo, statin–placebo, ACE inhibitor–statin, or placebo–placebo. Neither medication resulted in a change in albumin excretion over 2 to 4 years.